Meridian Bioscience (VIVO) Tops Q2 EPS by 8c, Offers Guidance

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.56, $0.08 better than the analyst estimate of $0.48. Revenue for the quarter came in at $85.3 million versus the consensus estimate of $84.5 million.

GUIDANCE:

Meridian Bioscience sees FY2021 EPS of $1.60-$1.80, versus the consensus of $1.66. Meridian Bioscience sees FY2021 revenue of $305-335 million, versus the consensus of $324 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Pfizer lung cancer drug misses survival goal in Phase 3 trial
• NVE Corporation names new CEO and expands board to seven members